Navigation Links
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
Date:12/17/2010

decisions. 

To learn more about ITG Majestic's unique healthcare research capabilities, please contact Christina Brown, Vice President of Healthcare Sales at: 646.584.6061, christina.brown@itg.com, or visit our website: www.healthcare.majesticresearch.com.ITG Media/Investor Contact:J.T. Farley(212) 444-62592010 Investment Technology Group, Inc. All rights reserved. Not to be reproduced or retransmitted without permission. Any unauthorized usage or transmission is strictly prohibited. Investment research products and services are offered by ITG Investment Research, Inc., and not ITG Inc. (a FINRA Member firm and SIPC Member). ITG, the ITG logo, and ITG Investment Research, Inc. are trademarks of Investment Technology Group, Inc. and its subsidiaries. All other trademarks, service marks, logos, and trade names are owned by their respective owners. #120810-29227

Any opinions, claims, forecasts or estimates in this marketing material are subject to risks, uncertainties and assumptions and there can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates.


'/>"/>
SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... conducting this study is to provide an overview ... global market for protein drugs/therapeutics. The key objective ... direction of protein drugs as an important tool ... report explores present and future strategies within the ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources Group finds ... Australia , China , ... Korea—will expand at a strong rate through 2023. Dental implant procedure ... and as patient awareness rises. Other key findings from ... dental implant market: , Dental implant penetration: ...
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe ... destination , today announced that it now offers the ... AirSense CPAPs are the first sleep apnea therapy devices ... simple and easy to track and share real-time data ... effectiveness of their CPAP therapy.  In addition, the internal ...
Breaking Medicine Technology:Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... BOSTON, Dec. 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) ... continued growth in 2012 through the development and sales ... treatment and management of medical conditions. In 2011, Solos ... approximately $300,000 in debt for the Company. The signed ...
... Dec. 29, 2011 Janssen Research & Development, LLC (JRD) ... Application (sNDA) to the U.S. Food and Drug Administration (FDA) ... an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular ... The filing is supported by data from the pivotal Phase ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 9Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 10Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 11
(Date:10/1/2014)... October 01, 2014 October is national ... and early detection plans while raising money for breast ... Breast Cancer Awareness Month in the effort to ... to promote the importance of having access to clean, ... may be linked to certain forms of cancer. ...
(Date:10/1/2014)... Two bicyclists began a journey on September 8, ... an effort to raise funds and awareness to the ... father-daughter team, plan to bike more than 4,000 miles ... in Key West Florida. Funds raised along their ... nonprofit organization that assists post-9/11 service members, their families, ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 This October, ... to consumer lab testing, is offering 10% off all ... DIBN10 when placing their order to save. The Center ... the United States are affected by Diabetes. Because many ... to go undiagnosed until it causes serious health problems. ...
(Date:10/1/2014)... The Oliver Law Group P.C. ... Other-Sonic Ultrasound Gel lawsuit web page to ... surrounding the 2011 Pseudomonas aeruginosa / bacterial infection ... Michigan, which was ultimately traced to the recalled ... Beaumont patients who allegedly became ill following exposure ...
(Date:10/1/2014)... The annual Social Security cost-of-living adjustment (COLA) ... a new forecast by The Senior Citizens League (TSCL) ... (CPI) data through August, TSCL forecasts that COLAs will be ... consecutive year of record low COLAs,” states TSCL Chairman, Ed ... in 1975,” he notes. , Over the past five years ...
Breaking Medicine News(10 mins):Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... Today, Functionalab, a revolutionary new line of health and ... Bendel on 5th Avenue in New York City. ... in partnership with a globally recognized developer of science-based ... quality, potency and effectiveness. , , ...
... Misonix, Inc. (Nasdaq: MSON ), a developer of ... used for the ablation of tumors and worldwide for other ... and nine months ended March 31, 2009. Michael A. ... Senior VP and Chief Financial Officer, will host a conference ...
... increase patient access to stroke specialists, especially in rural ... (TIA), once known as a "mini" or "warning" stroke, ... full-blown stroke, according to two separate scientific statements and ... of the American Heart Association . , Telemedicine ...
... Inc. (OTC Bulletin Board: DSCI), a provider of ... quarter 2009 results before market on Monday, May 18, 2009. ... day to discuss the results at 11:00 am EDT. Interested ... 98098954 to access the call. You may also access this ...
... option maximizes UHPLC or HPLC productivity via seamless ... all new and existing Corona detector customersCHELMSFORD, Mass., ... UHPLC detector with a Waters ACQUITY UPLC(R) ... a new Empower 2/Corona detector instrument-control software driver. ...
... Co., Inc., (NYSE Amex: TPI ), a ... in Chengdu, China, today,announced that management will hold a ... 11:00 a.m. EDT on Friday, May 15, 2009. Financial,results ... market closes. , Interested parties ...
Cached Medicine News:Health News:Functionalab Launches Exclusively at Henri Bendel Monday, May 11th, 2009 2Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 2Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 3Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 4Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 5Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 6Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 7Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 8Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 9Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 10Health News:Videoconferencing can increase patient access to stroke specialists 2Health News:Videoconferencing can increase patient access to stroke specialists 3Health News:Derma Sciences Announces Date of Its First Quarter 2009 Earnings Release and Conference Call 2Health News:ESA's Corona(R) Family of HPLC Detectors, Including the New Corona ultra(TM), Can Now be Controlled by Waters Empower(R) 2 Chromatography Software 2Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Third Quarter Earnings Conference Call on Friday, May 15, 2009 at 11:00 a.m. EDT 2
... IntraLase FS laser introduces new high precision ... now have the opportunity to offer their ... a microkeratome for creating the corneal flap. ... laser and proprietary IntraLASIK software, surgeons may ...
... Teco Diagnostics manufactures fine urine chemistry ... urine chemistry reagent strips from start ... offer more economical prices compared to ... quality. Teco Diagnostics urine reagent strips ...
... with diabetes continue to have a tremendous ... life of patients, in addition to the ... to be associated with elevated levels of ... of haemoglobin A1c (HbA1c) in a diabetic ...
The Lifestream Plus Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program....
Medicine Products: